At midday, the HSI settled at 25,316, down less than 1 point, with market turnover at HKD107.316 billion. The HSCEI finished at 8,394, down 2 points or 0.03%. The HSTECH concluded at 4,429, down 25 points or 0.58%.

For key techs, MEITUAN-W (03690.HK) fell off 2.73%; XIAOMI-W (01810.HK) declined 2.3%; BIDU-W (09888.HK) mounted 3.35% against the market after repurchasing about 554,200 shares for nearly HKD50 million; TENCENT (00700.HK) edged up 0.05%; and BABA-W (09988.HK) gained 0.6%.

Among blue chips, HAIDILAO (06862.HK) slumped 9.49% amid reports that co-founder Zhang Yong's wife Shu Ping made a substantial share reduction, with Morgan Stanley expecting short-term pressure on the stock price. LI NING (02331.HK) slid 6.18% after Nomura said the company's sales growth continued to slow. LENOVO GROUP (00992.HK), which tumbled 6% yesterday, rebounded 5.53% by midday. JD HEALTH (06618.HK) and WH GROUP (00288.HK) tumbled 5.03% and 4.24% respectively. PETROCHINA (00857.HK) added 1.16% as Brent oil futures approached USD100.

Optical communication stocks echoed overseas market gains this morning. YOFC (06869.HK) shot up 7.59%; ZJ INNOLIGHT (03308.HK) climbed 3.96%; TIME INTERCON (01729.HK) advanced 7.25%; while ASMPT (00522.HK) and FIT HON TENG (06088.HK) soared more than 4%.

PCB stocks led the upswing. KB LAMINATES (01888.HK) surged 3.1%, while KINGBOARD HLDG (00148.HK), DELTON (01989.HK) and VGT (02476.HK) elevated more than 2%.
~

AASTOCKS Financial News
Website: www.aastocks.com

Hiroo Ota, CEO of Kioxia (285A.JP) who took office in April, downplayed the possibility of deeper cooperation with rival and shareholder SK hynix Inc. (SKHY.US), while pledging to curb rising memory chip prices to avoid hurting long-term AI demand.

He said stronger cooperation with SK hynix could face antitrust obstacles and would also be difficult to coordinate with the manufacturing facilities jointly owned by Kioxia and Sandisk Corporation (SNDK.US). The three companies have not discussed joint production either.

Kioxia's NAND flash memory prices surged 70% QoQ in 2Q, after more than doubling in 1Q. Analysts on average expected the company's operating profit to amplify by more than nine times in the fiscal year ending March next year.

Ota said price increases have already gone too far and he has instructed the sales team not to seek substantial price hikes from data center operators, worrying that this could erode investment appetite in the AI sector, though he did not rule out further price increases in the future.
~

AASTOCKS Financial News
Website: www.aastocks.com

US stocks resumed trading after the holiday, with the three major indices closing down 0.3-1.2%. The DJIA ended down 628 points, or 1.18%, at 52,786. The Nasdaq fell 85 points, or 0.32%, to end at 26,421. The S&P 500 dropped 45 points, or 0.58%, to settle at 7,673.

Chip stocks and AI infrastructure shares broadly bucked the market trend to ascend. Intel Corporation (INTC.US) surged more than 9%. QUALCOMM Incorporated (QCOM.US) spiked more than 3% after the company reached a data center infrastructure agreement with Amazon to jointly develop customized AI chips.

Advanced Micro Devices, Inc. (AMD.US) also rallied 5.9%. SK hynix Inc. (SKHY.US) swelled 4.8%. However, Micron Technology, Inc. (MU.US) dipped 1.6%, while NVIDIA Corporation (NVDA.US) also dropped 2%.

Among mega-cap tech stocks, Apple Inc. (AAPL.US) and Microsoft Corporation (MSFT.US) lost more than 1.2%, while Tesla, Inc. (TSLA.US) shot up nearly 4%.
~

AASTOCKS Financial News
Website: www.aastocks.com

NEW YORK, Sept. 8, 2026 /PRNewswire/ -- As interest in tea-based beverages continues to grow across the United States, Mixue, a brand under MIXUE Group (02097.HK), is making specialty drinks more accessible through affordable pricing and diverse flavor offerings. This summer, the brand introduced six seasonal menu items across its U.S. stores, including the first-ever U.S. debut of Green Lemon Tea and Green Lemonade. The launch has generated positive consumer feedback and social media engagement, reinforcing Mixue's commitment to delivering quality-driven, value-forward beverages for everyday consumers.

A Growing U.S. Tea Market

Tea-based beverages continue to gain traction in the United States, one of the world's largest tea-importing markets. Iced tea remains the dominant format, while growing demand for ready-to-drink tea, fruit-infused beverages, and health-conscious options is helping expand the category. As consumers increasingly look for alternatives to sugary soft drinks, younger generations are driving tea consumption beyond traditional breakfast occasions and into everyday refreshment moments.

In this environment, Mixue entered the U.S. market with a simple proposition: making quality tea-based beverages and soft-serve ice cream available at prices that encourage everyday enjoyment. As the world's largest freshly-made beverage and food chain by store count, the brand has gained recognition in international markets for offering a broad range of products at accessible price points, making it easier for consumers to explore new tea flavors and fruit beverages.

A key part of Mixue's ability to maintain affordable pricing lies in its global supply chain and operational efficiency. The company's value proposition is not built on lowering product quality, but on economies of scale, integrated sourcing capabilities, and streamlined operations developed through years of international expansion. These advantages enable Mixue to continuously introduce new products while keeping prices within reach of everyday consumers, making quality tea-based beverages more accessible to a wider audience.

Summer Launch Validates Consumer Appeal

This summer's seasonal menu has provided another example of how that strategy resonates with consumers. Since launch, several limited-time offerings have received encouraging feedback, reflecting growing demand for refreshing tea drinks. Among them, the banana-themed beverages, including Banana MIXUE Shake and Creamy Banana, have generated notable discussion on social media, with customers sharing reviews, recommendations, and product photos online.

The launch has also helped introduce Mixue to new consumers, contributing to increased brand visibility and store traffic. Beyond product discussions, some customers have expressed interest in seeing Mixue expand into additional U.S. markets, reflecting growing recognition of the brand's combination of variety, affordability, and approachable flavors.

Looking ahead, Mixue plans to continue expanding its presence in the United States through new store openings and ongoing menu innovation. By combining quality ingredients, accessible pricing, and products tailored to evolving consumer preferences, the company aims to become an increasingly familiar part of everyday refreshment occasions and modern tea culture in America.

For more information about Mixue US, please visit https://www.instagram.com/mixue.us/.  

About MIXUE Group

MIXUE Group is the world's leading global freshly-made drinks company. Mixue has built a comprehensive end-to-end supply chain at the largest scale in China's freshly-made drinks industry, encompassing essential aspects covering procurement, production, logistics, R&D and quality control. The company is committed to delivering high-quality, affordable fresh beverages to consumers worldwide through its extreme-efficiency global supply chain and franchise model.

香港2026年9月8日 /美通社/ -- 近日，萬眾期待的BIGBANG 2026-2027 WORLD TOUR < XX : COSMOS > IN HONG KONG正式公佈！本次演唱會由TME live與ELF ASIA聯合主辦，傳奇天團BIGBANG將於2026年11月13日至15日，一連三日在香港啟德體育園主場館盛大舉行，屆時黃色皇冠將在啟德夜空下再次綻放光芒，見證王者歸來的歷史時刻。

本次香港站將採用分階段預售及公開發售的方式，具體安排如下：

• BIGBANG V.I.P 優先購票資格登記 | BIGBANG V.I.P MEMBERSHIP SURVEY: 9月2日 11:00AM - 9月8日 11:59PM
• BIGBANG V.I.P MEMBERSHIP 優先預售 | BIGBANG V.I.P MEMBERSHIP PRESALE: 9月14日 11:00AM - 11:59PM
• Visa優先預售 | Visa Pre-sale:
  • Visa Infinite卡持卡人專屬 Exclusive access for Visa Infinite Cardholders: 9月15日 10:00AM - 1:00PM
  • 中銀Visa卡持卡人專屬 Exclusive access for BOC Visa Cardholders: 9月15日 2:00PM - 7:00PM
  • 所有Visa卡持卡人專屬 Exclusive access for All Visa Cardholders: 9月15日 8:00PM - 11:00PM
• TME QQ音樂、JOOX、酷狗音樂 優先預售 | TME Pre-sale: 9月16日 11:00AM - 3:00PM
• Trip.com Group及Klook 優先預售 | Trip.com Group and Klook Pre-sale: 9月16日 5:00PM - 9:00PM
• 公開發售 | General On-sale: 9月17日12:00PM

BIGBANG 香港演唱會的成功舉辦，匯聚了多方力量的協同賦能。本次活動獲得 FWD 富衛保險、Visa、Trip.com Group、Klook、Samsung 的聯合贊助支持。各品牌依託自身平台優勢與資源，深度參與本次演出，將品牌理念與音樂文化相結合，共同為香港樂迷獻上高水準的現場演出。其中，Trip.com Group 與 Klook 作為本次香港站官方票務支持夥伴，依託各自旅行與本地生活平台能力，讓來自世界各地的V.I.P們都能順利見證這場傳奇演出。特別感謝啟德體育園主場館，對本次巡演香港站的大力支持。作為香港標誌性綜合體育與娛樂地標，啟德主場館可容納約 50,000 名觀眾，兼具全天候營運能力與頂級聲光適配性。正是在這樣一座連接城市記憶與未來盛事的場館裡，BIGBANG 的黃色皇冠將在 2026 年 11 月的夜空下升起。

關於BIGBANG

BIGBANG 是 YG 娛樂於 2006 年推出的男子組合。自出道單曲《Bigbang》發行以來，組合已成長為全球頂級藝人，並打造了《謊言》、《最後的問候》、《一天一天》、《FANTASTIC BABY》及《BANG BANG BANG》等多首熱門歌曲。

BIGBANG 在國內外音樂榜單上佔據主導地位，同時在各大頒獎禮上橫掃大獎，無論是團體還是個人成員，其作為音樂人的無限可能性均獲得了廣泛認可。2022 年，他們發行了數字單曲《春夏秋冬》，再次證明了其在全球音樂市場中的強大影響力。

BIGBANG 超越 K-pop 範疇，成為橫跨現場演出、時尚及大眾文化的標誌性存在，此前已通過北美、歐洲及亞洲的全球巡演實現售罄，證明了其世界範圍的影響力。

為紀念出道 20 週年，組合宣佈在美國 2026 年科切拉山谷音樂藝術節（Coachella Valley Music and Arts Festival）的舞台上重磅回歸，引發當地觀眾熱烈反響，再次印證了他們的非凡實力。今年 8 月，他們在高陽成功啓動了新一輪世界巡演，計劃通過 19 個城市共 36 場演出與全球粉絲見面。在出道 20 週年紀念日當天（8 月 19 日），BIGBANG 發行了時隔 4 年的新歌——數字單曲《BiiiG》，獲得了全球粉絲的熱烈喜愛。

關於TME live

TME live是由中國音樂娛樂服務領航者騰訊音樂娛樂集團全新構建，以Live演出為核心的複合型多元業務品牌，旨在通過線下演出籌辦及線上直播互動與線上演出兩種呈現形式，打破線上線下的音樂演出邊界，利用多場景、創新形態的演出模式與極速、超清的數字影音技術，打造音樂娛樂演出線上線下全景聲態。

• POLARIS-1研究共入組147例未控制中重度哮喘患者，基於前98例患者的中期分析結果顯示，SKB378/WIN378半衰期可高達75天，其臨床療效支持每年兩次給藥方案。
• SKB378/WIN378對FEV₁（均值增幅達174mL，經安慰劑校正的均值增幅最高達256 mL，p=0.033）、FeNO及血嗜酸性粒細胞計數等與哮喘急性發作密切相關的關鍵生物標誌物均產生了顯著且持久的作用。單次給藥後，上述效應快速出現，並持續至第24周。
• SKB378/WIN378耐受性及安全性良好，未觀察到治療相關嚴重不良事件、退出或停藥；治療組與安慰劑組的不良事件發生率相當，注射部位反應和抗藥物抗體發生率均較低。
• SKB378/WIN378的首項III期研究已啟動，旨在評估每年兩次給藥方案。第二項III期試驗計劃於2027年上半年啟動。

成都2026年9月8日 /美通社/ -- 四川科倫博泰生物醫藥股份有限公司(簡稱「科倫博泰」或「公司」)今日宣佈，合作夥伴Windward Bio已公佈POLARIS-1臨床試驗II期部分的積極中期結果，評估SKB378/WIN378每年兩次給藥方案治療哮喘的效果。

SKB378/WIN378 是一款新型全人源超長效單克隆抗體，具有獨特的結合模式，旨在抑制胸腺基質淋巴細胞生成素（TSLP）。該抗體經過工程化改造，具有更強的效力、延長的半衰期及效應功能沉默。SKB378/WIN378是目前已知唯一一款通過雙位點結合 TSLP來阻斷其信號通路的在研藥物，能夠干擾 TSLP 與其兩個共受體在上皮細胞表面的結合。

POLARIS-1是一項無縫銜接的全球性II/III期臨床研究。該研究的II期部分是一項為期48周、隨機、雙盲研究，將SKB378/WIN378的三個劑量水平與安慰劑進行對比，旨在評價SKB378/WIN378在未控制中重度哮喘患者中的藥代動力學、安全性、免疫原性和藥效學活性，同時評估其對肺功能和氣道炎症生物標誌物的影響，並為III期研究的劑量選擇提供依據。該II期部分共入組147例患者，超出初始120例的入組目標，其中中期分析基於前98例患者的數據。 

中期分析結果顯示，SKB378/WIN378單次給藥後第24周：

• FEV₁呈現劑量依賴性均值增加，最高達176mL (經安慰劑校正後的均值增幅最高達256 mL，p=0.033）。
• FeNO呈劑量依賴性均值降低，最高降幅達24 ppb（降幅百分比為43%，p=0.006）。
• 血嗜酸性粒細胞計數（EOS）均值降低，最高降幅達200 cells/µL（降幅百分比為51%，p<0.0001）。
• 上述效應最早於第2周即接近最大值，並持續至第24周。

SKB378/WIN378耐受性及安全性良好，至數據截止日期，未觀察到治療相關嚴重不良事件、退出或停藥。治療組與安慰劑對照組的不良事件發生率相當。注射部位反應發生率低於1%，抗藥物抗體（ADA）發生率為2%（該指標用於評估免疫原性），對SKB378/WIN378的藥理學特徵并無影響。中期分析結果及群體藥代動力學模型支持SKB378/WIN378採用每年兩次給藥方案。

科倫博泰首席執行官葛均友博士表示：「很高興看到SKB378/WIN378 POLARIS‑1研究的II期部分在合作夥伴的積極推動下取得了陽性結果。作為一款超長效抗TSLP的差異化抗體，該藥物可同時兼顧療效、安全性與患者依從性，有望解決中重度哮喘領域尚未被滿足的臨床需求。」

POLARIS-1的III期部分已由Windward Bio啟動，確定採用兩種每年兩次給藥的劑量方案，旨在評估SKB378/WIN378對重度哮喘患者的年化哮喘急性發作率及其他關鍵療效指標的影響。此外，Windward Bio計劃於2027年上半年啟動第二項III期臨床研究POLARIS-2。POLARIS-1 的II期研究數據將在即將召開的醫學會議上公佈。

SKB378/WIN378最初由科倫博泰與和鉑醫藥共同開發，雙方共同享有其全球權益。

註：FEV₁（第一秒用力呼氣容積）為肺功能的關鍵指標。FeNO（呼出氣一氧化氮分數）及EOS為與哮喘急性發作相關的關鍵炎症標誌物。

關於POLARIS-1研究

POLARIS-1（NCT07120503）是一項由Windward Bio開展的無縫銜接的全球性II/III期研究，旨在評估SKB378/WIN378用於未控制哮喘成人患者。其II期部分是一項隨機、雙盲研究，主要評估皮下注射SKB378/WIN378三個劑量水平相較於安慰劑的藥代動力學、安全性、免疫原性及藥效學活性，並為III期劑量選擇提供依據。其III期部分正在評估兩種每年兩次給藥劑量的SKB378/WIN378對比安慰劑的療效，主要終點為重度哮喘患者的年化哮喘急性發作率。

關於SKB378/WIN378

SKB378/WIN378是一款新型全人源、超長效單克隆抗體，具有獨特的結合模式，旨在抑制胸腺基質淋巴細胞生成素（TSLP）。該靶點已獲臨床驗證，在哮喘、慢性阻塞性肺疾病（COPD）、慢性鼻竇炎伴鼻息肉及嗜酸性粒細胞性食管炎等多種免疫性疾病的發生和進展中發揮關鍵作用。SKB378/WIN378經過工程化改造，具有更強的效力、延長的半衰期及效應功能沉默。SKB378/WIN378是目前已知唯一一款通過雙位點結合 TSLP來阻斷其信號通路的在研藥物，能夠干擾 TSLP 與其兩個共受體在上皮細胞表面的結合。II期研究中期分析結果支持其每年兩次給藥的潛力。SKB378/WIN378可顯著、持續且呈劑量依賴性地增加FEV₁（肺功能衡量指標），同時顯著且持續地降低FeNO和血嗜酸性粒細胞計數——上述均為與哮喘急性發作相關的關鍵標誌物。目前，SKB378/WIN378正在進行針對哮喘的全球性II/III期POLARIS-1研究和針對COPD的II期SIRIUS研究，其中第二項針對哮喘的關鍵性III期試驗POLARIS-2計劃於2027年上半年啟動。Windward Bio自科倫博泰（亦稱SKB378）與和鉑醫藥（亦稱HBM9378）獲得了該分子的全球權益（大中華區及部分東南亞和西亞國家除外）。

關於科倫博泰

四川科倫博泰生物醫藥股份有限公司(簡稱「科倫博泰」，股票代碼：6990.HK)是科倫藥業控股子公司，專注於創新生物技術藥物及小分子藥物的研發、生產、商業化及國際合作。公司圍繞全球和中國未滿足的臨床需求，重點佈局腫瘤、自身免疫和代謝等重大疾病領域，建設國際化藥物研發與產業化平台，致力於成為在創新藥物領域國際領先的企業。公司目前擁有30餘個重點創新藥項目，其中4個項目8個適應症已獲批上市，2個項目3個適應症處於NDA階段，10餘個項目正處於臨床階段。公司成功構建了享譽國際的專有ADC及新型偶聯藥物平台OptiDC^TM，已有2個ADC項目5個適應症獲批上市，多個ADC或新型偶聯藥物產品處於臨床或臨床前研究階段。瞭解更多，請訪問：https://www.kelun-biotech.com/ 

關於Windward Bio

Windward Bio是一家臨床階段的生物技術公司，在藥物發現、開發及商業化領域具備深厚的專業經驗，致力於為患有嚴重呼吸系統疾病和皮膚疾病（包括哮喘、COPD及特應性皮炎）的患者開發超長效抗體藥物。公司正在推進一系列針對經臨床驗證分子通路的潛在差異化生物制劑，旨在通過減少給藥頻率，在改善臨床結局的同時減輕患者的治療負擔。Windward Bio的核心管線WIN378是一款靶向TSLP的新型全人源單克隆抗體，該款抗體經工程化改造後具有更強的效力、延長的半衰期及效應功能沉默，正處於針對哮喘和COPD的臨床開發階段。公司的第二款管線產品WIN027是一款靶向TSLP和IL-13的超長效、人源化雙特異性抗體，正在開發用於呼吸系統疾病和皮膚疾病。Windward Bio成立於2024年，總部位於瑞士巴塞爾，在美國設有運營機構。如需瞭解更多信息，請訪問https://windwardbio.com/。

香港2026年9月8日 /美通社/ -- 近日，世界旅遊及旅行理事會（WTTC）正式官宣復星國際(656)旗下地中海度假集團（ClubMed Lifestyle Group）加入成為其全球會員。

地中海度假集團以Club Med為核心品牌，運營高端一價全包度假村，並以輕資產模式拓展度假場景服務，包括超級度假區和超級文旅目的地，持續構建多元化的度假生活方式。

按2025年營業額計算，地中海度假集團旗下Club Med，是全球最大的一價全包度假村品牌。目前，Club Med在全球六大洲40多個國家和地區運營69座度假村。地中海度假集團年接待賓客超過150萬人次，並預計到2030年將全球度假村數量擴展至約85座。自2025年底以來，地中海度假集團已在中國、加拿大、摩洛哥、巴西、美屬維爾京群島、印度尼西亞和意大利簽署新的度假村項目，同時加速在阿爾卑斯山、地中海及北非海岸、東北亞及東南亞、美洲及加勒比海地區的佈局，並積極探索中東市場。

今年7月，地中海度假集團旗下Club Med在巴黎總部與微軟簽署戰略合作備忘錄，微軟法國首席執行官科琳•德•比爾巴奧（Corinne De Bilbao）與地中海度假集團聯席總裁徐秉璸共同出席簽約儀式。雙方合作聚焦於AI驅動的賓客體驗、雲原生轉型及運營現代化。

WTTC全球會員身份代表着國際行業認可，而與微軟的合作則進一步強化了運營智能化水平。兩者相互促進，共同為地中海度假集團從69座度假村向2030年實現85座目標邁進，提供了堅實支撐。

French President Emmanuel Macron, after failing to push through a domestic ban on social media use by children under 15, has recently urged European Commission President Ursula von der Leyen to support legislation at the EU level.

In a letter dated August 29 to the EU executive body, Macron said issues including addictive designs, inadequate safeguards for adult accounts, and pornographic content were sufficient to justify the need for swift action at the EU level, and called for coordinated and unified legislation on the matter.

Countries including Greece, Germany, Spain, Italy, Portugal, Denmark, Sweden, Poland, Austria, Slovenia, Ireland and the Netherlands have all expressed interest in similar measures.
~

AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, Sept. 8, 2026 /PRNewswire/ -- Recently, the long-awaited BIGBANG 2026-2027 WORLD TOUR < XX: COSMOS > IN HONG KONG has been officially announced. Jointly organized by TME live and ELF ASIA, the legendary BIGBANG Tour in Hong Kong will be held at the Kai Tak Stadium from November 13^th to 15^th, 2026, an extravaganza of three nights in a row dedicated to its fans, during which the golden crowns will be lit up under the sky, witnessing the historic moment of the glorious return of the boy group.

For pre-sale and on-sale arrangements, the specifics are as follows:

• ️BIGBANG V.I.P MEMBERSHIP SURVEY: September 2, 11:00AM - September 8, 11:59PM
• ️BIGBANG V.I.P MEMBERSHIP PRESALE: September 14, 11:00AM - 11:59PM
• ️Visa Pre-sale:
  • Exclusive access for Visa Infinite Cardholders: September 15, 10:00AM - 1:00PM
  • Exclusive access for BOC Visa Cardholders: September 15, 2:00PM - 7:00PM
  • Exclusive access for All Visa Cardholders: September 15, 8:00PM - 11:00PM
• ️TME, QQ Music, JOOX and Kugou Music Pre-sale: September 16, 11:00AM - 3:00PM
• ️Trip.com and Klook Pre-sale: September 16, 5:00PM - 9:00PM
• General On-sale: September 17, 12:00PM

The BIGBANG World Tour < XX: COSMOS > IN HONG KONG concert was brought by the outstanding collaboration between multiple partners. The event is jointly sponsored and supported by FWD Insurance, Visa, Trip.com Group, Klook and Samsung. Each brand, relying on its own platform advantages and resources, has deeply engaged in the whole process to combine its brand concept with music culture, and to present a high-level live performance for Hong Kong music fans. It's worth mentioning that Trip.com Group and Klook, as the official ticketing partners, utilizing their respective travel and local-life service platforms, did their best to make sure the V.I.P fans from all over the world have the opportunity to witness this legendary performance. Special thanks to the Kai Tak Stadium for its strong support for this Tour in Hong Kong. As a landmark of comprehensive sports and entertainment in Hong Kong featuring round-the-clock operation and top-notch audio-visual effects, the Kai Tak Stadium can accommodate approximately 50,000 spectators — precisely a venue where audiences can indulge in past memories while anticipating future events, with the upcoming BIGBANG and its golden crowns rising under the sky of November 2026.

ABOUT BIGBANG

BIGBANG is a boy group launched by YG Entertainment in 2006. Since the release of their debut single [Bigbang], the group has grown into a top-tier global act, producing numerous hit songs such as 'Lie', 'Last Farewell', 'Haru Haru', 'FANTASTIC BABY', and 'BANG BANG BANG'.

Dominating domestic and international music charts while sweeping grand prizes at major awards ceremonies, BIGBANG has earned recognition for the limitless capabilities of both the group and its individual members as musicians. In 2022, they released the digital single 'Still Life', reaffirming their commanding presence across the global music market.

Transcending K-pop to become a cultural icon spanning live performance, fashion, and popular culture as a whole, BIGBANG has proven their worldwide influence by selling out world tours across North America, Europe, and Asia.

Reuniting to mark their 20th debut anniversary, the group announced their legendary comeback on the stage of the 2026 Coachella Valley Music and Arts Festival in the United States. Drawing an explosive response from the local crowd, BIGBANG proved that they still have what it takes. In August, they successfully kicked off their new world tour in Goyang and set to engage with fans worldwide through 36 performances across 19 cities. On August 19, their 20th debut anniversary, BIGBANG released their new digital single [BiiiG], their first new song in 4 years, receiving passionate love from all over the world.

About TME live

TME live is a diversified business brand centered on live performances, created by Tencent Music Entertainment Group, a leading music entertainment service provider in China. TME live creates an all-around music entertainment performance experience by combining online and offline performances, utilizing an innovative performance model and extremely fast, ultra-high-definition digital audio-visual technology.

• XPENG has officially commissioned its humanoid robot production lines and completed the production-lines manufacturing of the world's first advanced humanoid robot, which autonomously walked off the lines, marking a critical leap from R&D prototyping to production-lines manufacturing.

• XPENG's humanoid robot production lines feature core process automation exceeding 80%, setting a new manufacturing benchmark with a precision, flexible, and intelligent production line.

• XPENG extends its automotive-grade manufacturing capabilities to robotics, marking a critical step toward mass production.

GUANGZHOU, China, Sept. 8, 2026 /PRNewswire/ -- XPeng Inc. ("XPENG" or the "Company," NYSE: XPEV; HKEX: 9868), a leading global Physical AI company, today announced that its humanoid robot production lines are now in operation, and the world's first advanced general‑purpose humanoid robot made its debut by autonomously walking off the lines after completing production. This achievement signifies a key leap from R&D prototyping to line manufacturing and an important advance toward volume production.

Press Kit Link: https://wetransfer.com/downloads/64c97a585428373656af84cd175c55e820260908011306/cf28c8fe399b5db33258de769e27cca220260908011306/5cd228

XPENG's robot production lines are the world's first automated production lines for advanced humanoid robots, deeply integrating the mature automotive-grade quality systems of the smart electric vehicle industry with precision manufacturing for humanoid robot. Built to automotive-grade quality standards, it establishes a quality system for mass production of advanced humanoid robots. Designed for scale from day one, with over 80% of core processes automated, the lines deliver a high-precision, highly flexible, and intelligent manufacturing system, ensuring consistent critical-process quality and laying the foundation for scaled production and rapid capacity expansion.

He Xiaopeng, Chairman & CEO of XPENG, said: "The robot production lines were created from scratch with no precedent to follow. Today's step is small, but XPENG is building the production lines for an entirely new product category. Looking ahead, XPENG will continue to explore faster production rhythms and greater scale in robot manufacturing, charting a new path toward a leading robot manufacturing industry in China and globally."

As a key pillar of XPENG's Physical AI strategy, XPENG's next-generation IRON is an advanced humanoid robot combining highly human-like form and movement with AI-driven intelligence, designed to meet the highest safety standards. It is being developed as an advanced general-purpose humanoid robot platform, capable of supporting a broad range of applications and continuously improving through self-reinforcement in the real world.

XPENG IRON features an industry-leading human-like form and design, with a proprietary fully enclosed flexible lattice structure designed to balance aesthetics and safety. With 76 degrees of freedom (DOF) across the body and 21 in each hand, IRON delivers industry-leading levels of dexterity and mobility. On the intelligence side, XPENG IRON is powered by three Turing AI chips delivering up to 2,250 TOPS of effective computing power. This computing power enables XPENG to deploy its Physical AI foundation model directly on the robot, enabling IRON to autonomously perform complex tasks without remote operation, while ensuring low-latency inference and enhanced data security.

Mr. He said, "We aim to build a new type of robot with full generalization capabilities that can truly become part of everyday life, create a better life for people, and ultimately become a companion in their lives." And he put on a staff badge for IRON, symbolizing that it has officially become a member of the XPENG team.

Looking ahead, XPENG robots are scheduled to enter mass production by the end of this year, with initial commercial-scenario rollouts beginning in XPENG's own stores and campuses. Official market launch and delivery in China and overseas markets are planned for 2027.

XPENG remains committed to its physical-AI and globalization strategy, continuously building three growth curves: automotive, robotics, and globalization. The rollout of the first advanced general-purpose humanoid robot and the activation of the production lines mark another important milestone in the ongoing implementation of XPENG's physical-AI strategy. Given the high technical barriers and limited high-quality supply in the advanced general-purpose humanoid robot segment, the gross margin per unit is expected to be significantly higher than that of new energy vehicles. As XPENG's robotics business accelerates into scaled manufacturing and commercialization, its value as the Company's second growth curve is rapidly becoming visible.

On August 24, XPENG's robotics business has entered into share purchase agreements with multiple investors, raising over US$900 million at a post-money valuation of over US$6.3 billion, which marks the largest single-round private capital raise in China's embodied AI industry to date. This is a strong endorsement from the capital markets of XPENG Group's leading position, technology roadmap, scaled manufacturing capabilities, and long-term commercial value in the physical AI domain.

From a unified physical AI foundation model, to different intelligent embodiments, to scaled manufacturing, XPENG is progressively connecting the full chain from model base and product R&D to industrialized deployment, bringing AI out of the digital world into the real world, and into the broader physical world.

About XPENG

XPENG is a global leader in physical AI, dedicated to bringing artificial intelligence into the physical world and redefining future mobility and smart living. The company has built a full-stack self-developed physical AI technology system covering Turing AI chips, physical world foundation models, and highly integrated software and hardware applications. Based on its unified technology foundation, XPENG has developed products including smart electric vehicles, Robotaxi, and humanoid robots, driving the scaled deployment of physical AI. Headquartered in Guangzhou, China, XPENG has dual primary listings on the New York Stock Exchange and the Hong Kong Stock Exchange. With an international R&D, manufacturing, sales, and service system, XPENG brings smarter, safer, and better lifestyles to users worldwide through continuous technological innovation and an open physical AI ecosystem. For more information, please visit XPENG's official website at https://www.xpeng.com/.